This site is intended only for US Healthcare Professionals

Timeline Helix Image that scrolls down the page
Timeline image with milestones in hemophila treatment advances Timeline image with milestones in hemophila treatment advances
What is AAV Gene Therapy

With gene therapy, science is taking on the challenge to advance innovations

Gene therapy is an innovative approach to treating a disease by introducing a functional gene or inactivating/editing a disease-causing gene. To do this, gene therapy uses modified noninfectious viruses called “vectors” that can enter certain cells. The transfer of a working gene into those cells helps produce a functional protein.

Vector Icon

Focusing on adeno-associated virus (AAV) gene therapy

Gene therapies work through a variety of approaches including functional gene transfer. Functional genes are usually delivered into the cells of the body by inserting them into an inactivated viral shell (the vector), which carries the gene to specific target cells. The gene can be delivered directly to the person (in vivo gene therapy) or into cells that have been taken from the person, then treated, then returned to the person (ex vivo gene therapy).

The gene therapies for hemophilia B that are currently being studied in clinical trials use a certain type of vector called an adeno-associated virus, or AAV.

AAV-based gene therapy is built on trusted scientific advances and years of proven clinical research, creating breakthrough treatments for a variety of diseases over the past decade—two with FDA/EMA approvals—and more than 250 clinical trials currently underway.

Take a deeper Dive

Watch Dr. Pipe discuss why AAV vectors are used in gene therapy.

How AAV gene therapy works

AAV-based gene therapy uses nonpathogenic, nonreplicating viruses and consists of a capsid (vector) encasing a therapeutic gene (transgene). Through its design, it facilitates the accurate and efficient activation of the transgene inside its targeted destination, for example, the liver.

Targeting specific areas with AAV gene therapy

There are many different types of AAV vectors that can target specific areas of the body. Some AAV vectors are more precise in their targets, while others target a wider, less specific range of cells and tissues.

AAV vectors also have lower levels of immunogenicity compared with other viral vectors such as retroviruses, lentiviruses, and adenoviruses.

For liver-directed AAV gene therapy, serotypes AAV2, AAV5, AAV6, AAV8, and AAV9 have been shown to exhibit liver tropism, with some exhibiting narrower tropism than others.

Neutralizing antibodies (NAbs) can influence clinical outcomes

Neutralizing antibody image
  • Preexisting AAV antibodies from prior viral exposure can influence the outcomes of liver directed AAV gene therapy
  • Structurally distinct AAV serotypes may correlate with a lower prevalence of preexisting antibodies in the population

Take a deeper Dive

Watch Dr. Pipe discuss how targeted delivery of a gene is achieved using AAV vectors.

Keep up with the Evolving science OF GENE THERAPY FOR HEMOPHILIA B

Sign up for news of advances in gene therapy for hemophilia B.

SIGN UP NOW >

What would you like to know next?




Please select an answer
Thanks for letting us know. Let’s explore more about gene therapy and hemophilia B.
Learn More >

Why is AAV gene therapy promising for hemophilia B?